Form 4: Tyra Biosciences Director Gilla Kaplan Granted 22,200 Stock Options

Tyra Biosciences, Inc. Director Gilla Kaplan was granted 22,200 stock options with an exercise price of $9.25 as part of the company's Non-Employee Director Compensation Program.

Summary

• Reporting Person: Gilla Kaplan, a Director of Tyra Biosciences, Inc.
• Transaction Date: May 29, 2025.
• Transaction Type: Acquisition of 22,200 stock options (Right to Buy).
• Exercise Price: $9.25 per share.
• Grant Program: The options were granted pursuant to the Issuer's Non-Employee Director Compensation Program.
• Vesting Schedule: 1/12th of the total number of shares subject to the option will vest monthly following May 29, 2025, the date of grant.
• Accelerated Vesting: Any remaining unvested portion of the option will vest on the date of the next annual meeting of the Issuer's stockholders if it occurs prior to the first anniversary of the grant date, subject to continuous service.
• Expiration Date: The options expire on May 28, 2035.
• Beneficial Ownership: Following the transaction, Gilla Kaplan beneficially owns 22,200 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Neutral to slightly positive. This is a routine compensation event for a director, which is expected. The grant of options aligns the director's interests with shareholders, which is generally viewed favorably as it incentivizes long-term performance.

Positives

• The grant of stock options to Director Gilla Kaplan aligns her interests with those of shareholders, incentivizing long-term performance and value creation.
• The options were granted under the Issuer's Non-Employee Director Compensation Program, indicating a structured and formal approach to director compensation and corporate governance.

Negatives

• This filing primarily reports a compensation event and does not contain information that would typically be categorized as negative for the company's operational or financial performance.

Risks

• The document, being a Form 4, primarily reports insider transactions and does not detail company-specific operational or financial risks.

Future Outlook

The document details a stock option grant with a vesting schedule extending into the future, indicating an ongoing commitment to the director's service and aligning future incentives with the company's performance over the vesting period.

Management Comments

• No direct management comments or quotes are provided in this Form 4 filing, which is typical for this type of regulatory document.

Industry Context

The granting of stock options to non-employee directors is a standard practice across various industries, particularly in biotechnology, to attract and retain experienced board members and align their interests with long-term shareholder value. This practice is a common component of executive and director compensation packages aimed at fostering long-term commitment and performance.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is a common compensation practice in the biotechnology and pharmaceutical sectors, comparable to programs at companies like Moderna, BioNTech, or Regeneron, which often use equity incentives to attract and retain top talent and board members.
• The vesting schedule (monthly over a year, with potential acceleration upon an annual meeting) is also a standard mechanism to ensure continuous service and align long-term interests, consistent with industry benchmarks for director compensation.

Management Changes

Corporate Governance

Related Party Transactions

• The document reports a compensation grant (stock options) to a director, which is a standard transaction between the company and a related party (director) under a pre-approved compensation program.

Stakeholder Impact

• Shareholders: The grant aligns the director's long-term interests with shareholder value creation, potentially leading to more focused governance and strategic decisions.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• Monthly vesting of 1/12th of the granted stock options will commence following May 29, 2025.
• Potential accelerated vesting of any remaining unvested options if the next annual stockholders' meeting occurs before the first anniversary of the grant date.
• Gilla Kaplan may exercise the vested stock options at the exercise price of $9.25 per share at any time before the expiration date of May 28, 2035.

Key Dates

Recommendation

Keywords

Tyra Biosciences, TYRA, Gilla Kaplan, stock options, Form 4, insider transaction, director compensation, equity grant, SEC filing